LignaMed Overview
Update this profile
LignaMed General Information
Description
Developer of molecule therapy intended to offer breakthrough treatments for severe asthma, organ transplant viability, and fibrosis. The company develops therapeutics from flaxseed derivatives obtained through proprietary synthesis processes and also offers an oral treatment for Th2-low asthma, to salvage donor lung organs that are currently not suitable for a lung transplant, enabling patients to improve donor lung storage conditions and extend the donor lung preservation period, as an oral treatment for Pulmonary Fibrosis control and in some cases reverse the progression of the disease.
Contact Information
Want to dig into this profile?
We’ll help you find what you need
Learn more
LignaMed Valuation & Funding
Deal Type
Date
Amount
Raised to Date
Post-Val
Status
Stage
7. Grant
01-Sep-2018
$916K
Completed
6. Grant
18-Jul-2017
00000
Completed
5. Grant
01-Jan-2020
00.000
Completed
Startup
4. Grant
01-Jan-2019
00.000
Completed
Startup
3. Grant
01-Jan-2018
00000
Completed
Startup
2. Grant
01-Jan-2017
$403K
Completed
Startup
1. Accelerator/Incubator
10-Mar-2015
Completed
Startup
To view LignaMed’s complete valuation and funding history, request access »
LignaMed Patents
7
Total Documents
Applications and Grants
000
Total Patents
Families
000
Granted
000
Pending
000
Expiring
in next 12 mo
LignaMed Recent Patent Activity
Publication ID
Patent Title
Status
First Filing Date
Technology (CPC)
Citations
AU-2018283958-B2
Process for the preparation of (s,s)-secoisolariciresinol diglucoside and (r,r)-secoisolariciresinol diglucoside
Inactive
12-Jun-2017
000000000
EP-3638220-A4
Process for the preparation of (s,s
Pending
12-Jun-2017
000000000
JP-2020523394-A
Method for producing (s,s)-secoisolariciresinol diglucoside and (r,r)-secoisolariciresinol diglucoside
Pending
12-Jun-2017
000000000
US-20200181187-A1
Process for the preparation of (s,s)-secoisolariciresinol diglucoside and (r,r)-secoisolariciresinol diglucoside
Inactive
12-Jun-2017
000000000
CA-3065386-A1
Process for the preparation of (s,s)-secoisolariciresinol diglucoside and (r,r)-secoisolariciresinol diglucoside
Pending
12-Jun-2017
C07H1/00
To view LignaMed’s complete patent history, request access »
LignaMed Board Members (5)
Name
Representing
Role
Since
James Harris
Self
Chairman
000 0000
Melpo Christofidou-Solomidou Ph.D
LignaMed
Founder & Chairman of Scientific Advisory Board
000 0000
Michael Dishowitz Ph.D
Self
Board Member
000 0000
Philip Sass Ph.D
Self
Board Observer & Advisor
000 0000
You’re viewing 4 of 5 board members. Get the full list »
LignaMed Signals
Growth Rate
0.80%
Weekly Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial